Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2019

29.01.2019 | review

Surgical concepts in esophageal cancer

verfasst von: Dr. Paolo Nicola Camillo Girotti, Prim. Prof. Dr. Ingmar Königsrainer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Summary

Despite neoadjuvant treatment being available for esophageal cancer, surgery remains the cornerstone of treatment. The aim of this article is to give a clear and simple overview of current issues in the available surgical strategies relating to locally limited and advanced disease, including the following: clinical staging, preoperative general condition and comorbidities, surgical strategy, surgical approaches, postoperative complications and the role of surgery in advanced disease. Based on a literature search and our personal professional experience to date, enhanced surgical treatment protocols for the treatment of the adenocarcinomas of esophagogastric junction (AEG) and the squamous cell carcinoma of the esophagus are presented and discussed. Eligibility for a surgical resection strongly depends on the stage of the tumor and on the comorbidities. A minimally invasive laparoscopic approach should be preferred in the case of limited disease, regardless of its histology, or limited/advanced intrathoracic squamous cell carcinoma (hybrid technique: laparoscopic approach combined with thoracotomy). The surgical strategy in the case of adenocarcinoma to achieve radical resection depends on the tumor location. Finally, surgery should be performed by a multidisciplinary team that includes medical oncologists, radiation oncologists, gastroenterologists, dieticians and physiotherapists, so as to minimize the postoperative complications rates and improve early postoperative outcomes and overall patient survival. Therefore, we support the centralization of treatment of esophageal cancer to high volume centers.
Literatur
1.
Zurück zum Zitat Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390:2383–96.CrossRef Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390:2383–96.CrossRef
3.
Zurück zum Zitat Kassis ES, Kosinski AS, Ross P, et al. Predictors of anastomotic leak after esophagectomy: an analysis of the society of thoracic surgeons general thoracic database. Ann Thorac Surg. 2013;96:1919–26.CrossRef Kassis ES, Kosinski AS, Ross P, et al. Predictors of anastomotic leak after esophagectomy: an analysis of the society of thoracic surgeons general thoracic database. Ann Thorac Surg. 2013;96:1919–26.CrossRef
4.
Zurück zum Zitat Kechagias A, van Rossum PSN, Ruurda JP, van Hillegersberg R. Ischemic conditioning of the stomach in the prevention of esophagogastric anastomotic leakage after esophagectomy. Ann Thorac Surg. 2016;101:1614–23.CrossRef Kechagias A, van Rossum PSN, Ruurda JP, van Hillegersberg R. Ischemic conditioning of the stomach in the prevention of esophagogastric anastomotic leakage after esophagectomy. Ann Thorac Surg. 2016;101:1614–23.CrossRef
5.
Zurück zum Zitat Goense L, van Rossum PSN, Kandioler D, et al. Stage-directed individualized therapy in esophageal cancer. Ann N Y Acad Sci. 2016;1381:50–65.CrossRef Goense L, van Rossum PSN, Kandioler D, et al. Stage-directed individualized therapy in esophageal cancer. Ann N Y Acad Sci. 2016;1381:50–65.CrossRef
6.
Zurück zum Zitat Findlay JM, Bradley KM, Maile EJ, et al. Pragmatic staging of oesophageal cancer using decision theory involving selective endoscopic ultrasonography, PET and laparoscopy. Br J Surg. 2015;102:1488–99.CrossRef Findlay JM, Bradley KM, Maile EJ, et al. Pragmatic staging of oesophageal cancer using decision theory involving selective endoscopic ultrasonography, PET and laparoscopy. Br J Surg. 2015;102:1488–99.CrossRef
7.
Zurück zum Zitat Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl. 5):v50–v7.CrossRef Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl. 5):v50–v7.CrossRef
9.
Zurück zum Zitat Li S‑J, Wang Z‑Q, Li Y‑J, et al. Diabetes mellitus and risk of anastomotic leakage after esophagectomy: a systematic review and meta-analysis. Dis Esophagus. 2017;30:1–12.CrossRef Li S‑J, Wang Z‑Q, Li Y‑J, et al. Diabetes mellitus and risk of anastomotic leakage after esophagectomy: a systematic review and meta-analysis. Dis Esophagus. 2017;30:1–12.CrossRef
10.
Zurück zum Zitat Nienhueser H, Kunzmann R, Sisic L, et al. Surgery of gastric cancer and esophageal cancer: does age matter? J Surg Oncol. 2015;112:387–95.CrossRef Nienhueser H, Kunzmann R, Sisic L, et al. Surgery of gastric cancer and esophageal cancer: does age matter? J Surg Oncol. 2015;112:387–95.CrossRef
11.
Zurück zum Zitat Wei R, Dong W, Shen H, et al. Predictive effects of lung function test on postoperative pneumonia in squamous esophageal cancer. Sci Rep. 2016;6:23636.CrossRef Wei R, Dong W, Shen H, et al. Predictive effects of lung function test on postoperative pneumonia in squamous esophageal cancer. Sci Rep. 2016;6:23636.CrossRef
12.
Zurück zum Zitat van Adrichem EJ, Meulenbroek RL, Plukker JTM, et al. Comparison of two preoperative inspiratory muscle training programs to prevent pulmonary complications in patients undergoing esophagectomy: a randomized controlled pilot study. Ann Surg Oncol. 2014;21:2353–60.PubMed van Adrichem EJ, Meulenbroek RL, Plukker JTM, et al. Comparison of two preoperative inspiratory muscle training programs to prevent pulmonary complications in patients undergoing esophagectomy: a randomized controlled pilot study. Ann Surg Oncol. 2014;21:2353–60.PubMed
13.
Zurück zum Zitat Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.CrossRef Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.CrossRef
14.
Zurück zum Zitat Al-Batran SE, Pauligk C, Homann N, Schmalenberg H, Kopp HG, Haag GM, Luley KB, Schmiegel Wolff H, Folprecht G, Probst S, Prasnikar N, Thuss-Patience PC, Trojan J, Goetze TO, Meiler J, Schuler MH, Jäger E, Hofheinz RD. LBA-008Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO). Ann Oncol. 2017; https://doi.org/10.1093/annonc/mdx302.007.CrossRef Al-Batran SE, Pauligk C, Homann N, Schmalenberg H, Kopp HG, Haag GM, Luley KB, Schmiegel Wolff H, Folprecht G, Probst S, Prasnikar N, Thuss-Patience PC, Trojan J, Goetze TO, Meiler J, Schuler MH, Jäger E, Hofheinz RD. LBA-008Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO). Ann Oncol. 2017; https://​doi.​org/​10.​1093/​annonc/​mdx302.​007.CrossRef
15.
Zurück zum Zitat Haverkamp L, Seesing MF, Ruurda JP, et al. Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer. Dis Esophagus. 2017;30:1–7.PubMed Haverkamp L, Seesing MF, Ruurda JP, et al. Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer. Dis Esophagus. 2017;30:1–7.PubMed
16.
Zurück zum Zitat Glatz T, Marjanovic G, Kulemann B, et al. Hybrid minimally invasive esophagectomy vs. open esophagectomy: a matched case analysis in 120 patients. Langenbecks Arch Surg. 2017;402:323–31.CrossRef Glatz T, Marjanovic G, Kulemann B, et al. Hybrid minimally invasive esophagectomy vs. open esophagectomy: a matched case analysis in 120 patients. Langenbecks Arch Surg. 2017;402:323–31.CrossRef
17.
Zurück zum Zitat Rinieri P, Ouattara M, Brioude G, et al. Longterm outcome of open versus hybrid minimally invasive Ivor Lewis oesophagectomy: a propensity score matched studydagger. Eur J Cardiothorac Surg. 2017;51:223–9.PubMed Rinieri P, Ouattara M, Brioude G, et al. Longterm outcome of open versus hybrid minimally invasive Ivor Lewis oesophagectomy: a propensity score matched studydagger. Eur J Cardiothorac Surg. 2017;51:223–9.PubMed
18.
Zurück zum Zitat Briez N, Piessen G, Bonnetain F, et al. Open versus laparoscopically-assisted oesophagectomy for cancer: a multicentre randomised controlled phase III trial—the MIRO trial. BMC Cancer. 2011;11:310.CrossRef Briez N, Piessen G, Bonnetain F, et al. Open versus laparoscopically-assisted oesophagectomy for cancer: a multicentre randomised controlled phase III trial—the MIRO trial. BMC Cancer. 2011;11:310.CrossRef
20.
Zurück zum Zitat Markar S, Gronnier C, Duhamel A, et al. Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option? J Clin Oncol. 2015;33:3866–73.CrossRef Markar S, Gronnier C, Duhamel A, et al. Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option? J Clin Oncol. 2015;33:3866–73.CrossRef
21.
Zurück zum Zitat Brusselaers N, Mattsson F, Lagergren J. Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis. Gut. 2014;63:1393–400.CrossRef Brusselaers N, Mattsson F, Lagergren J. Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis. Gut. 2014;63:1393–400.CrossRef
Metadaten
Titel
Surgical concepts in esophageal cancer
verfasst von
Dr. Paolo Nicola Camillo Girotti
Prim. Prof. Dr. Ingmar Königsrainer
Publikationsdatum
29.01.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0467-0

Weitere Artikel der Ausgabe 1/2019

memo - Magazine of European Medical Oncology 1/2019 Zur Ausgabe